Skip to search formSkip to main contentSkip to account menu

rivastigmine

Known as: Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1), (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate, M-((S)-1-(Dimethylamino)ethyl)phenyl Ethylmethylcarbamate 
A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in… 
National Institutes of Health

Related topics

Related topics

18 relations
24 HR rivastigmine 0.192 MG/HR Transdermal System24 HR rivastigmine 0.192 MG/HR Transdermal System [Exelon]Alzheimer's DiseaseCarbamates

Broader (2)

Cholinesterase InhibitorsNeuroprotective Agents

Narrower (1)

Exelon

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide.
Highly Cited
2007
Highly Cited
2007
Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET
RationaleMarked reduction in the cortical nicotinic acetylcholine receptors is observed in the brain of patients suffering from… 
Highly Cited
2007
Highly Cited
2007
Characterization of reversible and pseudo-irreversible acetylcholinesterase inhibitors by means of an immobilized enzyme reactor.
Review
2006
Review
2006
Do cholinergic therapies have disease-modifying effects in Alzheimer’s disease?
Highly Cited
2004
Highly Cited
2004
Prediction of treatment response to rivastigmine in Alzheimer’s dementia
Objectives: To predict the treatment response to rivastigmine in patients with Alzheimer’s dementia using neuropsychological and… 
Highly Cited
2004
Highly Cited
2004
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients
Cholinesterase inhibitors (ChEIs) have shown positive symptomatic effects on cognition, activities of daily living, and behavior… 
2003
2003
Influence of cholinergic circuitries in generation of high-frequency somatosensory evoked potentials
Review
2002
Review
2002
CLINICAL AND COST-EFFECTIVENESS OF DONEPEZIL, RIVASTIGMINE, AND GALANTAMINE FOR ALZHEIMER'S DISEASE
Objectives: Systematic review of the clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for people… 
Review
2001
Review
2001
Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.
Review
1963
Review
1963
Action of Trace Elements on the Metabolism of Fluoride
Many studies in laboratory animals have shown that the absorption of fluoride can be influenced by dietary factors, thus… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)